It is well established from previous studies that tumours which overexpress the ErbB2 (HER2) receptor are more likely to be endocrine resistant due to the increased activation of growth factor pathways.63 Another important discovery here was the association of pZIP7 to the proto-oncogene c-Fos. The gene discussed is ERBB2; the disease is neoplasm.